

Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile

<https://marketpublishers.com/r/CCE58B132CAEN.html>

Date: November 2010

Pages: 125

Price: US\$ 5,700.00 (Single User License)

ID: CCE58B132CAEN

Abstracts

Introduction

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

Gain insight into Chugai's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Chugai over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

Benchmark Chugai's performance against key rivals in the prescription

pharmaceutical sector

Assess the strong sales performance of the company's monoclonal antibody (MAb) franchise, positioning Chugai as the leading Japanese MAb player

Contents

EXECUTIVE SUMMARY

Key findings

Prescription pharmaceutical sales and growth rate performance, 2003–15

Financial performance, 2003–15

Chugai: PharmaVitae forecasts at a glance

Strategic insight

[Missing title]

Chugai dominates the Japanese MAb landscape

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

About

ABOUT THIS PROFILE

PharmaVitae Explorer database

Chapter structure

Quarterly news update

Company introduction

Company sales

Company financials

Key products and competitors

Data sourcing

Analyst consensus

QUARTERLY NEWS UPDATE

Latest prescription pharma product news

Q1 2010

Q4 2009

Q3 2009

Q2 2009

Q1 2009

COMPANY INTRODUCTION

Key findings

Background

Key corporate developments

M&A history

Consolidation into the Roche group in October 2002
Divestments since the Roche merger have promoted prescription pharmaceuticals focus
Current corporate structure

COMPANY SALES

Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
 Product analysis, 2003–09
 Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
 Explanation of launch/core/expiry analysis
 Launch analysis, 2009–15
 Core analysis, 2009–15
 Expiry analysis, 2009–15
 Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis

COMPANY FINANCIALS

Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
 Operating costs and profit analysis, 2003–09
 Operating cost ratio and profit margin analysis, 2003–09
 Operating cost ratio and profit margin analysis, 2009–15
 Operating costs and profit analysis, 2008–14

KEY PRODUCTS AND COMPETITORS

Key findings
Overview
Oncology

[Missing title]

Herceptin

Rituxan

Neutrogin

Tarceva

Hematology

Epogin

R-744/Mircera

Immunology & inflammation

[Missing title]

Infectious disease

Tamiflu

Pegasys

Genitourinary

Evista

APPENDIX

References

Abbreviations

Exchange rates

I would like to order

Product name: Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile

Product link: <https://marketpublishers.com/r/CCE58B132CAEN.html>

Price: US\$ 5,700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCE58B132CAEN.html>